LONDON - 11th March 2014 - A large pool of undiagnosed patients and the growing population of the elderly in both Europe and North America point to a massive end-user market for sleep disorder diagnostics devices. The market is steadily drawing investors due to the visible tilt in preference from drugs to home care sleep tests that are more convenient and lack side effects.
New analysis from Frost & Sullivan US & European Market for Sleep Disorder Diagnostic Devices finds that the market earned revenue of $95.6 million in 2013 and estimates this to reach $125.8 million in 2017. The diagnostic devices covered in this research include clinical polysymnogram (PSG) and ambulatory PSG systems.
Information technology is playing an increasingly important role in the transformation of the sleep disorder treatment market. Disruptive technologies that are patient friendly, easy to operate and safe are finding considerable uptake among elderly patients considering their interest in alternatives to medications and traditional sleep disorder tests.
"There is a growing demand for devices that offer integration and connectivity in sleep centres and home settings," said Frost & Sullivan Healthcare Research Analyst Akanksha Joshi. "In this environment, cloud-based services could very likely change the dynamics of the market."
Another factor that could tip the balance in favour of home care devices is the limited availability of technicians, which leads to long waiting hours. The lower rate of specialized physicians also reduces the total number of tests being conducted, thus reducing the number of sleep centres present. Furthermore, the market is grappling with the issue of inadequate numbers of technically sound sales personnel, which lowers the number of units sold.
Despite these considerable challenges, participants can shore up their sales by addressing the specific needs of the elderly. Manufacturers are already collaborating with sleep centres, primary care physicians, and third-party companies that facilitate the renting of devices to satisfy market needs and build robust relations with customers.
"Vendors that offer self-help devices have the potential to erode the share of sleep centres that offer sleep tests, as self-help technology can decrease the number of visits to physicians and overnight stays in clinics," noted Joshi. "Overall, a manufacturer that offers accurate data through real-time device connectivity involving the insurer and physicians as well as a precise predictive model for better patient outcomes will elicit greater interest in its product line."
For more information on this analysis, please email Anna Zanchi, Corporate Communications, at firstname.lastname@example.org.
US & European Market for Sleep Disorder Diagnostic Devices is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Overview of Current Day Healthcare Challenges - Is Efficiency the Driver, Home Care Ventilation - The Favoured Choice of Care, Medical Tourism in Eastern Europe - Enabling Technology and Shaping the Future of Medical Care and Future looks "cold" for Wound management - Cold Fusion. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion
Corporate Communications – Europe
P: +39.02.4851 6133